Asthma: Complete Guide to Diagnosis, Treatment, and Long-Term Management

Asthma is a chronic inflammatory disease of the airways characterized by variable airflow obstruction, bronchial hyperresponsiveness, and underlying inflammation. It affects an estimated 339 million people globally, making it one of the most common chronic respiratory conditions. While asthma cannot be cured, it can be effectively controlled with appropriate pharmacotherapy and self-management strategies, allowing most patients to lead fully active lives. The Global Initiative for Asthma (GINA) provides evidence-based guidelines that are updated annually and form the backbone of modern asthma management worldwide.

Asthma is not a single disease but rather a heterogeneous syndrome with multiple phenotypes. Allergic (atopic) asthma — the most common type, especially in children — is driven by immunoglobulin E (IgE)-mediated responses to environmental allergens such as house dust mites, pollen, pet dander, and mold. Non-allergic asthma may be triggered by respiratory infections, exercise, cold air, air pollution, occupational exposures, or stress, without demonstrable IgE-mediated sensitization. Eosinophilic asthma is characterized by elevated eosinophils in sputum and blood, often presenting as severe adult-onset disease that may be less responsive to standard inhaled corticosteroids. Regardless of phenotype, the common pathophysiological thread is chronic airway inflammation leading to structural changes (airway remodeling), including goblet cell hyperplasia, subepithelial fibrosis, smooth muscle hypertrophy, and increased vascularity.

Common triggers include allergens (dust mites, pollen, animal dander, cockroach), respiratory infections (rhinovirus is the most common precipitant of exacerbations), exercise (especially in cold dry air), tobacco smoke and air pollution, occupational agents (isocyanates, flour dust, wood dust), medications (aspirin and NSAIDs in aspirin-exacerbated respiratory disease; non-selective beta-blockers), and strong emotions or stress. Classic symptoms include episodic wheezing, shortness of breath, chest tightness, and cough — often worse at night or early morning. Red flags requiring urgent evaluation include inability to speak in full sentences, use of accessory respiratory muscles, oxygen saturation below 92%, silent chest on auscultation, and altered consciousness. Any of these indicate a life-threatening asthma attack requiring immediate emergency treatment.

Diagnosis is based on a compatible clinical history plus objective demonstration of variable expiratory airflow limitation. Spirometry is the gold standard: a reduced FEV1/FVC ratio (below 0.70 in adults) with significant reversibility after bronchodilator administration (increase in FEV1 of 200 mL and 12% or more from baseline) confirms the diagnosis. When spirometry is normal, bronchial provocation testing with methacholine or mannitol can demonstrate airway hyperresponsiveness. Peak expiratory flow (PEF) monitoring, while less accurate than spirometry, is valuable for ongoing self-monitoring — variability exceeding 10% in adults suggests asthma. Fractional exhaled nitric oxide (FeNO) above 50 ppb in adults supports a diagnosis of eosinophilic airway inflammation and predicts responsiveness to inhaled corticosteroids. Blood eosinophil count and total IgE may help phenotype the disease and guide biologic therapy selection.

GINA organizes asthma treatment into five steps of escalating therapy intensity. The guiding principle is to achieve good symptom control and minimize future risk (exacerbations, fixed airflow limitation, side effects) using the lowest effective treatment step. Step 1 (mild intermittent): as-needed low-dose ICS-formoterol (the preferred GINA track) or as-needed SABA with low-dose ICS taken whenever the SABA is used. Step 2 (mild persistent): daily low-dose ICS (e.g., budesonide 200-400 mcg/day or fluticasone propionate 100-250 mcg/day) with as-needed SABA, or as-needed low-dose ICS-formoterol. Step 3 (moderate): low-dose ICS-LABA maintenance (e.g., budesonide/formoterol, fluticasone/salmeterol) plus as-needed SABA or as-needed ICS-formoterol. Step 4: medium-dose ICS-LABA, possibly adding tiotropium (a long-acting muscarinic antagonist) or leukotriene receptor antagonist (montelukast). Step 5 (severe): high-dose ICS-LABA plus add-on therapies including tiotropium, biologic agents (omalizumab for allergic asthma, mepolizumab/benralizumab for eosinophilic), and if necessary, low-dose oral corticosteroids (prednisone). Treatment is stepped up when control is inadequate for 2-3 months and stepped down after 3 months of good control.

Short-acting beta-2 agonists (SABAs) such as salbutamol (albuterol) — typically 100 mcg per actuation, 1-2 puffs as needed — have been the traditional rescue medication for acute asthma symptoms. Salbutamol works within minutes by relaxing airway smooth muscle via beta-2 adrenergic receptor stimulation. However, GINA now recommends against SABA-only treatment (without any ICS) even in mild asthma, because SABA monotherapy does not address the underlying inflammation and is associated with increased risk of severe exacerbations and death. The preferred reliever in GINA's Track 1 is as-needed low-dose ICS-formoterol (a LABA with rapid onset), which provides both bronchodilation and anti-inflammatory benefit with each use.

Inhaled corticosteroids (ICS) are the cornerstone of asthma controller therapy. Budesonide and fluticasone propionate are the most widely used, available in dry powder inhalers (DPI), metered-dose inhalers (MDI), and nebulizer solutions. ICS reduce airway inflammation, decrease exacerbation frequency, improve lung function, and reduce asthma mortality. Long-acting beta-2 agonists (LABAs) such as formoterol and salmeterol are always used in combination with ICS (never alone in asthma) to provide sustained bronchodilation. Formoterol has the unique advantage of rapid onset (1-3 minutes), making it suitable for both maintenance and reliever therapy (MART strategy). Leukotriene receptor antagonists (LTRAs) — montelukast 10 mg daily — may be added as adjunctive therapy, particularly in patients with concomitant allergic rhinitis or aspirin-sensitive asthma. Tiotropium bromide, a long-acting muscarinic antagonist originally developed for COPD, is approved as add-on therapy in poorly controlled asthma at Steps 4-5.

For patients with severe asthma uncontrolled on high-dose ICS-LABA plus additional controllers, biologic therapies target specific inflammatory pathways. Omalizumab (anti-IgE) was the first biologic approved for asthma — administered subcutaneously every 2-4 weeks based on body weight and IgE level, it reduces exacerbations by approximately 50% in allergic asthma. Anti-IL-5 agents (mepolizumab, benralizumab) and anti-IL-4R alpha (dupilumab) target eosinophilic inflammation. Anti-TSLP (tezepelumab) is effective across asthma phenotypes. Selection of the appropriate biologic depends on the patient's inflammatory phenotype, biomarkers (blood eosinophils, FeNO, total IgE), and comorbidities.

Every asthma patient should have a written asthma action plan that specifies daily controller medications, how to recognize worsening asthma (symptoms, PEF readings), when and how to adjust treatment (increase reliever use, add oral corticosteroids), and when to seek emergency care. Traffic-light action plans use green (well-controlled), yellow (caution — step up treatment), and red (medical emergency) zones. Regular review of inhaler technique is essential — studies consistently show that 50-80% of patients use their inhalers incorrectly, significantly reducing drug delivery to the lungs.

Exercise-induced bronchoconstriction (EIB) occurs in up to 90% of asthma patients and in 10-15% of the general population. Pre-treatment with salbutamol 15-20 minutes before exercise is effective, but daily ICS use reduces EIB frequency. Warm-up exercises and breathing through the nose can help mitigate symptoms. During pregnancy, uncontrolled asthma poses greater risk to mother and fetus (pre-eclampsia, preterm birth, low birth weight) than asthma medications do. Budesonide is the preferred ICS in pregnancy (most safety data available), and treatment should not be stepped down during pregnancy. Salbutamol remains safe as a reliever. The principle is clear: it is safer to take asthma medications during pregnancy than to have uncontrolled asthma.

For more information on specific medications discussed in this article, explore the PillsCard drug pages: salbutamol, fluticasone, budesonide, formoterol, montelukast, tiotropium, omalizumab, and prednisone. Always consult your physician or pharmacist before starting or changing asthma medications.